Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis

Abstract Background Our primary aim was to assess the ability of a non-profit foundation-sponsored clinic network to facilitate access to specialized care for patients with neurofibromatoses (NF), a group of neurogenetic disorders including NF1, NF2, and schwannomatosis (SWN). Our secondary aim was...

Full description

Bibliographic Details
Main Authors: Vanessa L. Merker, Annie Dai, Heather B. Radtke, Pamela Knight, Justin T. Jordan, Scott R. Plotkin
Format: Article
Language:English
Published: BMC 2018-08-01
Series:BMC Health Services Research
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12913-018-3471-5
_version_ 1811202794711941120
author Vanessa L. Merker
Annie Dai
Heather B. Radtke
Pamela Knight
Justin T. Jordan
Scott R. Plotkin
author_facet Vanessa L. Merker
Annie Dai
Heather B. Radtke
Pamela Knight
Justin T. Jordan
Scott R. Plotkin
author_sort Vanessa L. Merker
collection DOAJ
description Abstract Background Our primary aim was to assess the ability of a non-profit foundation-sponsored clinic network to facilitate access to specialized care for patients with neurofibromatoses (NF), a group of neurogenetic disorders including NF1, NF2, and schwannomatosis (SWN). Our secondary aim was to identify how our findings in NF could be applied more broadly to other rare diseases. Methods We retrospectively reviewed aggregate data on patient volume reported by specialty NF clinics in a nonprofit network from 2008 to 2015. We classified clinics as high or low volume for disease type (NF1 and NF2/schwannomatosis) and pediatric/adult care. We compared clinic-level data to self-reported patient-level data from a large online patient registry. Results Between 2008 and 2015, the number of certified NF clinics grew from 32 to 50, and annual patient volume rose from 6776 to 10,245 patients (13% of the total estimated U.S. NF patient population). For patient registry participants (n = 4476), the median driving distance to the nearest network clinic was 51.3 miles. Driving distances to reach high-volume centers were elevated for adults compared to children (295.8 vs. 67.9 miles), and schwannomatosis and NF2 patients compared to NF1 patients (310.9 vs. 368.1 vs. 161.7 miles). Of registry participants reporting their location of care (n = 2271), only 43.2% received care in a network specialty clinic, with especially low rates of attendance in the Southwest and Far West. Conclusions While the number of certified NF clinics and volume of patients seen in these clinics has increased, many NF patients still do not attend specialty clinics and/or travel a significant distance for care. Geographic access to care is more limited for adults, patients with rarer conditions, and patients in the Western U.S. Potential measures to improve access to specialty care for people living with NF and other rare diseases are discussed.
first_indexed 2024-04-12T02:45:36Z
format Article
id doaj.art-cd7f70c449e4481381a22d02d59e6c96
institution Directory Open Access Journal
issn 1472-6963
language English
last_indexed 2024-04-12T02:45:36Z
publishDate 2018-08-01
publisher BMC
record_format Article
series BMC Health Services Research
spelling doaj.art-cd7f70c449e4481381a22d02d59e6c962022-12-22T03:51:12ZengBMCBMC Health Services Research1472-69632018-08-011811910.1186/s12913-018-3471-5Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosisVanessa L. Merker0Annie Dai1Heather B. Radtke2Pamela Knight3Justin T. Jordan4Scott R. Plotkin5Department of Neurology and Cancer Center, Massachusetts General HospitalDepartment of Neurology and Cancer Center, Massachusetts General HospitalChildren’s Tumor FoundationChildren’s Tumor FoundationDepartment of Neurology and Cancer Center, Massachusetts General HospitalDepartment of Neurology and Cancer Center, Massachusetts General HospitalAbstract Background Our primary aim was to assess the ability of a non-profit foundation-sponsored clinic network to facilitate access to specialized care for patients with neurofibromatoses (NF), a group of neurogenetic disorders including NF1, NF2, and schwannomatosis (SWN). Our secondary aim was to identify how our findings in NF could be applied more broadly to other rare diseases. Methods We retrospectively reviewed aggregate data on patient volume reported by specialty NF clinics in a nonprofit network from 2008 to 2015. We classified clinics as high or low volume for disease type (NF1 and NF2/schwannomatosis) and pediatric/adult care. We compared clinic-level data to self-reported patient-level data from a large online patient registry. Results Between 2008 and 2015, the number of certified NF clinics grew from 32 to 50, and annual patient volume rose from 6776 to 10,245 patients (13% of the total estimated U.S. NF patient population). For patient registry participants (n = 4476), the median driving distance to the nearest network clinic was 51.3 miles. Driving distances to reach high-volume centers were elevated for adults compared to children (295.8 vs. 67.9 miles), and schwannomatosis and NF2 patients compared to NF1 patients (310.9 vs. 368.1 vs. 161.7 miles). Of registry participants reporting their location of care (n = 2271), only 43.2% received care in a network specialty clinic, with especially low rates of attendance in the Southwest and Far West. Conclusions While the number of certified NF clinics and volume of patients seen in these clinics has increased, many NF patients still do not attend specialty clinics and/or travel a significant distance for care. Geographic access to care is more limited for adults, patients with rarer conditions, and patients in the Western U.S. Potential measures to improve access to specialty care for people living with NF and other rare diseases are discussed.http://link.springer.com/article/10.1186/s12913-018-3471-5NeurofibromatosisSchwannomatosisRare diseasesHealth service researchHealth services accessibilityHealthcare disparities
spellingShingle Vanessa L. Merker
Annie Dai
Heather B. Radtke
Pamela Knight
Justin T. Jordan
Scott R. Plotkin
Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis
BMC Health Services Research
Neurofibromatosis
Schwannomatosis
Rare diseases
Health service research
Health services accessibility
Healthcare disparities
title Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis
title_full Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis
title_fullStr Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis
title_full_unstemmed Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis
title_short Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis
title_sort increasing access to specialty care for rare diseases a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1 neurofibromatosis 2 and schwannomatosis
topic Neurofibromatosis
Schwannomatosis
Rare diseases
Health service research
Health services accessibility
Healthcare disparities
url http://link.springer.com/article/10.1186/s12913-018-3471-5
work_keys_str_mv AT vanessalmerker increasingaccesstospecialtycareforrarediseasesacasestudyusingafoundationsponsoredclinicnetworkforpatientswithneurofibromatosis1neurofibromatosis2andschwannomatosis
AT anniedai increasingaccesstospecialtycareforrarediseasesacasestudyusingafoundationsponsoredclinicnetworkforpatientswithneurofibromatosis1neurofibromatosis2andschwannomatosis
AT heatherbradtke increasingaccesstospecialtycareforrarediseasesacasestudyusingafoundationsponsoredclinicnetworkforpatientswithneurofibromatosis1neurofibromatosis2andschwannomatosis
AT pamelaknight increasingaccesstospecialtycareforrarediseasesacasestudyusingafoundationsponsoredclinicnetworkforpatientswithneurofibromatosis1neurofibromatosis2andschwannomatosis
AT justintjordan increasingaccesstospecialtycareforrarediseasesacasestudyusingafoundationsponsoredclinicnetworkforpatientswithneurofibromatosis1neurofibromatosis2andschwannomatosis
AT scottrplotkin increasingaccesstospecialtycareforrarediseasesacasestudyusingafoundationsponsoredclinicnetworkforpatientswithneurofibromatosis1neurofibromatosis2andschwannomatosis